Your session is about to expire
← Back to Search
Study Summary
This trial will test the safety and effectiveness of the drug SGN-STNV for treating solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition has not improved with standard treatments or I cannot tolerate them.Participants must have a tumor in a specific location that meets certain requirements.I have not had another cancer or any signs of cancer in the last 3 years.I do not have severe nerve pain or damage.I have previously been treated with drugs containing MMAE.My breast cancer is not HER2 positive.My condition has not improved with standard treatments or I cannot tolerate them.I have active cancer spread to my brain.You have a detectable tumor according to specific guidelines at the start of the study.I have cancer cells in the fluid around my brain and spinal cord.I am fully active or restricted in physically strenuous activity but can do light work.I haven't had a severe infection in the last 2 weeks.I have ovarian cancer.I have cervical cancer.My condition is specified in the trial's disease focus.I have been diagnosed with non-small cell lung cancer.My kidney, liver, and blood functions are all within normal ranges.
- Group 1: SGN-STNV
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial still recruiting participants?
"Yes, according to clinicaltrials.gov, this medical research is currently open for recruitment. The trial was launched on January 18th 2021 and last edited November 23rd 2022; it seeks 315 participants at 15 sites."
What has been the verdict of regulatory authorities regarding SGN-STNV?
"Due to the scant amount of evidence for SGN-STNV's safety and efficacy, our team at Power gave this drug a score of 1."
What are the intended outcomes of this clinical exploration?
"The main objective of the study, to be monitored over a span of up to 3 years post-treatment, is tracking laboratory abnormalities. Additional secondary goals include assessing overall survival rate, duration of response efficiency and peak plasma concentration time."
What is the reach of this research project?
"15 sites are participating in this medical trial, including the University of Ottawa / Ottawa General Hospital, The Angeles Clinic and Research Institute, Beth Israel Deaconess Medical Center as well as a dozen additional locations."
To what extent is the study population involved in this research?
"Indeed, per the information on clinicaltrials.gov, this research endeavor is actively seeking out eligible candidates. It was first published on January 18th 2021 and last modified November 23rd 2022. 315 participants are required for data collection at 15 trial sites."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger